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Abstract 8 
The treatment of ciprofloxacin (CIP) and ibuprofen (IBU) in test solutions by 9 
ferrate(VI) was investigated in this study. A series of jar test was performed in bench-10 
scale at pH 6–9 and ferrate(VI) dose of 1–5 mg/L. Results demonstrated that 11 
ferrate(VI) removed CIP from test solutions efficiently, with above 70% of reduction 12 
under study conditions. In contrary, the removal rates of IBU were very low, less than 13 
25% in all conditions. Raising ferrate(VI) dose could improve the treatment 14 
performance, while the influence of solution pH was not significant at pH 6–9. In 15 
addition, kinetic studies of ferrate(VI) with both compounds were carried out at pH 8 16 
and pH 9 (20 ?). Ferrate(VI) had a much higher reactivity with CIP than IBU at pH 8 17 
and pH 9, with CIP’s apparent second-order rate constants of 113.7 ± 6.3 M−1 s−1 and 18 
64.1 ± 1.0 M−1 s−1, respectively. The rate constants of ferrate(VI) with IBU were less 19 
than 0.2 M−1 s−1 at pH 8 and pH 9. Furthermore, seven oxidation products (OPs) were 20 
formed during CIP oxidised by ferrate(VI). The attack on the piperazinyl ring of the 21 
CIP by ferrate(VI) appeared to lead to the cleavage or hydroxylation of the rings, and 22 
Manuscript
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the attack on the quinolone moiety by ferrate(VI) might lead to the cleavage of the 23 
double bond at the six-member heterocyclic ring. No OP of IBU was detected during 24 
ferrate(VI) oxidation due to very small part of  IBU was degraded by ferrate(VI).   25 
Key words: Ciprofloxacin; Ferrate(VI); Ibuprofen; ?Kinetics; Oxidation products; 26 
Waste water treatment  27 
 28 
1 Introduction 29 
In recent years, the fate and environmental impact of pharmaceuticals present in 30 
the nature has gained increasing attention, among which antibiotics and non-steroidal 31 
anti-inflammatory drugs (NSAID) represent two most frequently detected therapeutic 32 
group in the environment (Comeau et al. 2008;, Lindqvist et al. 2005; Ternes 1998). 33 
Ciprofloxacin (CIP), as one of the first generation fluoroquinolones (FQs), shows 34 
broad activity against both gram-positive and gram-negative bacteria (Lee et al. 2007). 35 
Ibuprofen (IBU) is one of the most widely used groups of over-the-counter (OTC) 36 
NSAID. Both chemicals (Table 1) were in the 10 high priority list of pharmaceuticals 37 
relevant for water cycle (de Voogt et al. 2009), and commonly present in raw sewage, 38 
effluents of sewage treatment plants (STP) and surface waters with the concentration 39 
up to dozens of μg/L (Hartmann  et al. 1998; Jiang et al. 2013).  40 
Table 1 Information about CIP and IBU 41 
 42 
Exposure of pharmaceuticals present in the aquatic environment will pose 43 
negative impact to human beings and the eco-system although the chronic effects still 44 
require further research (Crane et al. 2006; Santos et al. 2010). Therefore, a number of 45 
studies on eliminating pharmaceuticals from the aquatic environment have been 46 
carried out recently including ozonation, chemical oxidation and several advanced 47 
oxidation processes (AOPs) (De la Cruz et al. 2012; De Witte et al. 2008, 2009; Lee 48 
et al 2012; Wols et al 2012 ). 49 
As an alternative, ferrate(VI) (FeO42−) is a promising dual-functional chemical as 50 
an oxidant and a subsequent coagulant (Fe3+ or Fe(OH)3), which has been 51 
successfully applied into many water remediation processes (Jiang 2013). Hence, 52 
several researches on the elimination of pharmaceuticals by ferrate(VI) have been 53 
conducted recently. Kinetic profiles of ferrate (VI) with some pharmaceuticals along 54 
with transforming by-products have been identified (Lee and von Gunten 2010; 55 
Sharma 2006, 2008). In addition, results on treating effluents from wastewater 56 
treatment plants (WWTPs) by ferrate(VI) demonstrate good performance on the 57 
elimination of pharmaceuticals containing electron-rich moieties (ERMs) (Lee et al. 58 
2009; Yang et al. 2012; Jiang et al., 2012). Solution pH has been proved to affect the 59 
treatment of many organic matters by ferrate (VI) (Graham et al. 2004; Lee et al. 60 
2005a), e.g. phenolic compounds. However, these studies gave little information on 61 
the treatment of CIP and IBU by ferrate(VI) in terms of optimum conditions such as 62 
solution pH and ferrate(VI) dose, and the oxidation products (OPs) formation. Hence, 63 
the objectives of this study were: 1) to assess the influence of solution pH and 64 
ferrate(VI) dose on the removal of CIP and IBU; 2) to compare the rate constants of 65 
ferrate(VI) with CIP and IBU; and (3) to identify the OPs of CIP and IBU during 66 
ferrate(VI) oxidation. To our best knowledge, this is the first paper to study the OPs 67 
of CIP and IBU during ferrate(VI) treatment. 68 
2. Experimental section 69 
2.1. Chemical and reagents 70 
Ciprofloxacin (CIP), ibuprofen (IBU), ibuprofen sodium and potassium 71 
ferrate(VI) (>90%) were purchased from Sigma-Aldrich (UK); ciprofloxacin 72 
hydrochloride was bought from VWR (UK); other chemicals and reagents used were 73 
obtained from Fisher Scientific (UK). The solubility of CIP and IBU was very low in 74 
water, thus ciprofloxacin hydrochloride and ibuprofen sodium of high solubility in 75 
water were used for kinetic studies. For the writing purpose, ciprofloxacin 76 
hydrochloride and ibuprofen sodium are still marked as CIP and IBU in this paper, 77 
respectively. All chemicals and reagents were used without further purification. 78 
Experimental water was generated by an Elga PureLab Option–R 7/15 pure water 79 
system (Veolia Water, France). The ferrate(VI) working solution (1 g/L) was freshly 80 
prepared by the addition of solid K2FeO4 to 0.0125 M Na2B4O7·10H2O/0.005 M HCl 81 
buffer solution at pH 9.0. Stock solutions of CIP and IBU were prepared separately in 82 
methanol at 100 mg/L, which were used for jar testing experiments and identification 83 
of OPs. Besides, for kinetic studies, stock solution of CIP and IBU were separately 84 
prepared in pure water at 1 g/L. 85 
2.2. Jar testing experiments 86 
Test solutions of 1 L with two levels of initial concentrations for each compound, 87 
100 and 10 μg/L, were prepared in buffer solutions at pH 6–9, the pH range which is 88 
usually applied in the practical water and wastewater treatment. Buffer solutions used 89 
were 0.05 M KH2PO4/0.005–0.05 M NaOH for pH 6–8 and 0.0125 M 90 
Na2B4O7·10H2O/0.005 M HCl for pH 9. 91 
A series of jar testing experiments was performed with a six-unit stirrer (Kemira 92 
flocculator 2000, Kemwater) under the following protocol: fast mixing for 1 min at 93 
400 rpm; slow mixing for 60–180 min at 40 rpm; and then sedimentation for 60 min. 94 
The ferrate(VI) dose applied was 0–5 mg/L as Fe. All experiments were conducted in 95 
duplicate. 96 
Certain amount of the supernatant was filtered sequentially by 1.2 μm glass fibre 97 
filters (Fisher Scientific, UK) and 0.45 μm membrane filters (Milipore, USA) after 98 
sedimentation. Solution pH of the filtrate was adjusted to 2.5 by 1 M H2SO4 and then 99 
subject to solid phase extraction (SPE) and further analysis by high performance 100 
liquid chromatography (HPLC)-UV.  101 
2.3. Kinetic studies 102 
Kinetic studies of ferrate(VI) with CIP and IBU were performed at pH 8 and pH 9 103 
at room temperature under pseudo first-order conditions with the pharmaceuticals in 104 
excess. The room temperature was 20±2 ? throughout the kinetic studies. A low 105 
ferrate(VI) dosage (2.5–10 μM) was applied to lower the self-decomposition rate of 106 
ferrate(VI), which were also determined at pH 8 and pH 9. The 500-mL buffered test 107 
solutions were stirred at 200 rpm and added with ferrate(VI) solution. At certain time 108 
intervals, aliquots of the reacting solution were quenched with ABTS solution. The 109 
remaining ferrate(VI) was then measured by the ABTS method at 415 nm (Lee et al. 110 
2005b) at a DR3900 Vis spectrophotometer (Hach-Lange, USA).  Briefly, the stock 111 
solutions of ABTS reagent were prepared by dissolving 0.01 g 2,2’-azino-bis(3-112 
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (Sigma-Aldrich) in 0.01 L 113 
pure water (1.82 mM) and stored at 4 ?C. Besides, 50 mM KHP/0.1 mM HCl was 114 
used as the buffer solution for pH 4. For the determination of ferrate (VI), 0.5 mL of 115 
the reacting solution was added into a mixed solution in a glass vial containing 1.42 116 
mL pH 4.0 buffer solutions and 0.08 mL 1 g/L ABTS reagent. After the complete 117 
reaction between ABTS and ferrate (VI) (within 1 second), which generates green 118 
radical cations (ABTS·+), the absorbance of the ABTS·+ solutions was measured at 119 
415 nm using 1 cm path-length cuvettes. The corresponding ferrate (VI) concentration 120 
was calculated based on the molar absorptivity of 3.4 × 104 M−1 cm−1. The kinetic 121 
runs were performed in triplication under each condition. 122 
2.4. Identification of Oxidation Products 123 
Test solutions of 10 mg/L target compounds were prepared separately in pure 124 
water. Two levels of ferrate(VI) doses (5 mg/L and 10 mg/L as Fe) were applied into 125 
the stirred test solutions at 200 rpm to investigate whether the higher dose (10 mg/L) 126 
would improve the formation of OPs. Besides, the solution pH was carefully adjusted 127 
by 0.01 M H2SO4 or 0.02 M NaOH to make the final pH at 6.5–7.5. Certain amount of 128 
the solution was filtered by 0.45 μm Puradisc syringe filters (Whatman, USA) after 129 
the reaction was completed. Then the solution pH was adjusted to 2.5 using 1 M 130 
H2SO4 for further liquid chromatography (LC)-mass spectrometry (MS) analysis. The 131 
experiments were operated in parallel under identical conditions. 132 
2.5. Analytical Methods 133 
The remaining pharmaceutical compounds present in the treated test solutions 134 
were enriched by solid phase extraction (SPE). The SPE cartridges employed were 135 
Strata-X 1 g/12 mL giga tubes (Phenomenex, UK). Generally, the extraction method 136 
was: (1) condition: 6 mL methanol; (2) equilibrate: 6 mL water; (3) loading samples: 137 
desired amount of water samples under vaccum at a flow rate of 5–10 mL/min; (4) 138 
wash: 2 × 6 mL water; (5) dry: 15 min under gentle nitrogen flow; and (6) elute: 2 × 6 139 
mL 2:49:49 (v/v/v) formic acid/methanol/acetonitrile. The elutes were evaporated to 140 
dryness at 50 °C using a DB-2A Dri-Block (Techne, UK), and then re-constituted to 1 141 
mL by 50:50 (v/v) methanol/water. The final enriched samples were filtered by 0.45 142 
μm Puradisc syringe filters (Whatman, USA) and then subject to HPLC analysis. 143 
An Agilent 1100 system (Agilent Technologies, USA) with a diode array detector 144 
(DAD) was employed for the measurement of target compounds. The column utilised 145 
for the separation of compounds was a 2.6 μm, 100 mm × 2.10 mm reversed phase 146 
Kinetex XB-C18 column (Phenomenex, UK). The column was kept at 25 °C and 147 
eluted by acetonitrile (Solvent A) and 0.1% formic acid in pure water (Solvent B) at a 148 
flow rate of 0.2 mL/min. The elution was initiated with 20% solvent A. Then the 149 
percentage of solvent A was increased to 45% over the next 6 min, held at this 150 
percentage for 15 min and finally lowered to 20% in 1 min. The DAD wavelengths 151 
for CIP and IBU detection were pre-determined and set at 280 nm and 220 nm, 152 
respectively. 153 
An Agilent 1100 HPLC plus a Bruker Daltonics Esquire 3000 ion trap MS were 154 
employed to identify OPs of target compounds treated by ferrate (VI). The separation 155 
was achieved by an Atlantis C18 column (3 μm, 150 mm × 2.1 mm, Waters, USA) 156 
using a gradient of acetonitrile (Solvent A)/ ammonium formate and formic acid in 157 
water (pH 3.5, Solvent B) at 0.2 mL/min. Solvent A was initially 1% and maintained 158 
at this percentage for 2 min. Then the percentage was increased to 30% in the next 1 159 
min and stayed at 30% till 20 min. After, the percentage of solvent A was gradually 160 
increased from 20% to 99% in 13 min, maintained at the same level for 9 min, and 161 
finally back to 1% in 1 min. CIP was analysed in electrospray ionisation (ESI) 162 
positive mode, while IBU was analysed in ESI negative mode. 163 
3. Results and discussion 164 
3.1. Effect of solution pH on the removal of mixed CIP & IBU 165 
To investigate the effect of solution pH on the ferrate(VI) performance to treat 166 
mixed CIP and IBU solutions, a series of jar-test experiments under buffered 167 
conditions at pH 6–9 was performed at two initial concentration levels: 100 μg/L and 168 
10 μg/L for each compound. 169 
Initial concentration of 100 μg/L 170 
Generally, CIP removal in the mixed solution samples by ferrate(VI) was not 171 
significantly affected by the solution pH (Fig. 1a). Though there was a slight 172 
fluctuation in CIP removal versus solution pH at 1 mg/L ferrate(VI), the average 173 
reduction rates of CIP by 1–5 mg/L ferrate(VI) under four pH conditions were above 174 
80%. More specifically, when the ferrate(VI) dose reached or exceeded 2 mg/L, the 175 
removal efficiencies of CIP by ferrate(VI) levelled off at 90 ± 2% between pH 6 and 176 
pH 9. On the other hand, when the dose of ferrate(VI) was 1 mg/L, CIP reduction 177 
peaked at pH 9 and bottomed at pH 8, with the removal efficiency of 91.5% and 178 
83.8%, respectively. Nevertheless, solution pH in the range of 6–9 played a minor 179 
role in the removal of CIP by ferrate(VI). 180 
The influence of solution pH on IBU removal was slightly stronger under 181 
relatively high ferrate(VI) doses (4–5 mg/L) than that under low doses (1–3 mg/L). 182 
More specifically, in the low dose range (1–3 mg/L), IBU removal rates were below 183 
13% and the influence of solution pH could be neglected. On the other hand, when the 184 
ferrate(VI) dose exceeded 3 mg/L, IBU removal at pH 6 was slightly higher than 185 
those under other pH conditions, with the biggest gap of 7% observed at 4 mg/L 186 
ferrate(VI). However, comparing with CIP, the reduction efficiency of IBU in the 187 
mixed solution with pH range of 6–9 was much lower than that of CIP by at least 60%. 188 
 189 
Fig. 1 The removal of compounds at 100 μg/L versus solution pH: (a) CIP; and (b) 190 
IBU 191 
 192 
Initial concentration of 10 μg/L 193 
The influence of solution pH on the removal of CIP became slightly stronger 194 
when the initial concentration was lowered from 100 μg/L to 10 μg/L (Fig. 2a). 195 
Specifically, when the ferrate(VI) dose exceeded 1 mg/L, the reduction rates of CIP at 196 
pH 6 and pH 8 were slightly higher than those at pH 7 and pH 9. The CIP removal by 197 
ferrate(VI) bottomed at 1 mg/L ferrate(VI) when the solution pH was 6, with the 198 
removal rate of about 70%. Nevertheless, the difference in the CIP removal at 199 
different pH was within 15% in the applied dose range, with all the removal 200 
efficiencies above 70%. 201 
For IBU removal, the removal efficiencies at pH 6 were slightly greater than 202 
those at pH 7–9 by about 5% when relatively low ferrate(VI) doses were applied (1–3 203 
mg/L), as shown in Fig. 2b . In the relatively high dose range (4–5 mg/L), IBU 204 
removal rates at pH 6–7 were similar, a little higher than those at pH 8–9. Nonetheless, 205 
the removal of IBU by ferrate(VI) was still much lower than that of CIP at this 206 
concentration level, with all the reduction rates less than 20%.  207 
 208 
Fig. 2 The removal of compounds at 10 μg/L versus solution pH: (a) CIP; and (b) 209 
IBU 210 
 211 
Generally, the solution pH at pH 6–9 did not exert significant influence on the 212 
ferrate(VI) oxidation of both CIP and IBU at two concentration levels.  The pKa value 213 
of HFeO4− is 7.3. In the applied pH range 6–9, ferrate(VI) undergoes the equilibrium 214 
of protonation/de-protonation (HFeO4- ↔ FeO42- + H+). The mono-protonated 215 
ferrate(VI) species, HFeO4-, has been considered the most reactive species of 216 
ferrate(VI) [16]. When the solution pH was increased from 6 to 9, the fraction of 217 
HFeO4-  in the solution decreased accordingly, which very likely meant the oxidation 218 
ability of ferrate(VI) solution decreased as well. On the other hand, CIP has a 219 
secondary amine moiety in its piperazinyl group, which is an electron-rich moiety 220 
(ERM). Ferrate(VI) usually has great reactivity with ERMs-containing compounds 221 
[18, 19]. Thus, the high reactivity of ferrate(VI) with CIP appeared to make the 222 
influence of solution pH (pH 6–9) on CIP removal be negligible. IBU, on the other 223 
hand, has no ERMs in its structure, and such compounds without ERMs are usually 224 
hard to be degraded by ferrate(VI) [18, 19]. Thus the removal of IBU was less than 225 
25% under all conditions. Such low removal rate also made the influence of solution 226 
pH (pH 6–9) on IBU removal negligible. The partial IBU removal could be attributed 227 
to the subsequent coagulation process initiated by the degradation of ferrate(VI) to 228 
ferric(III). 229 
3.2. Kinetics 230 
Kinetics of ferrate(VI) with CIP and IBU were studied under pseudo first-231 
order conditions at pH 8 and pH 9. The concentrations of target compounds were at 232 
least ten times higher than that of ferrate (VI). Thus, the reaction could be regarded as 233 
first-order with respect to [Fe(VI)]. The experimental results also confirmed this first-234 
order relationship. As shown in Fig. 3, the plot of ferrate(VI) degradation versus 235 
reaction time fitted nicely to single exponential decay with good coefficient of 236 
correlation (0.997), which suggests that the reaction is first-order with respect to 237 
[Fe(VI)] (Sharma et al. 2012). The pseudo first-order rate constants (k’) were 238 
determined at different concentrations of target compounds. In addition, the k’ values 239 
were corrected with the ferrate(VI) self-decay rate at pH 8 and pH 9 (Table 2). The k’ 240 
values obtained at different concentrations showed a linear relationship to [CIP] (Fig. 241 
4), which indicates the reactions are also first-order with respect to [CIP]. Therefore, 242 
the apparent second-order rate constant (kapp) for the reaction was then determined as 243 
the slope of the plot k’ versus [CIP]. The kinetic runs of ferrate (VI) with IBU were 244 
performed following the same procedure. The kapp values for both compounds are 245 
stated in Table 3. 246 
 247 
Fig. 3 Degradation of ferrate (VI) versus reaction time in the CIP solution at pH 9 248 
 249 
Table 2 Self-decomposition rates of ferrate (VI) at pH 8 and pH 9 250 
 251 
Fig. 4 k’ values versus [CIP] at pH 9 252 
 253 
Table 3 Apparent second-order rate constants of CIP and IBU at pH 8 and pH 9 254 
 255 
The kapp values of CIP were four orders of magnitude higher than the kapp values 256 
of IBU at pH 8 and pH 9. IBU contains a carboxylic group, which is an electron-257 
withdrawing functional group and can depress the reactivity of aromatic ring with 258 
ferrate(VI) (Yang et al. 2012).  Thus, the low reactivity of ferrate(VI) with IBU may 259 
be attributed to the carboxylic functional group in its structure. The decreasing 260 
solution pH increased the rate constants for both CIP and IBU, which is in agreement 261 
with many other studies (Sharma et al. 2006a, 2006b) and has been explained in the 262 
early section.  263 
 264 
3.3. Oxidation products 265 
The IBU removal by 5 mg/L and 10 mg/L ferrate(VI) were very low as shown 266 
in Table 4. Besides, no OP of IBU was detected in its treated solutions. In treating test 267 
solution samples with initial concentrations of 100 μg/L and 10 μg/L, up to 20% of 268 
IBU could be removed by 5 mg/L ferrate(VI). The extremely low remove rates of 269 
IBU obtained in this section might be explained by: 1) the slight removal of IBU by 270 
ferrate(VI) was very likely attributed to the coagulation effect of ferric ions reduced 271 
from ferrate(VI); and 2) the test solutions in this section were stirred at 200 rpm 272 
constantly, which was not ideal for the formation and aggregation of flocs and then 273 
reduced the coagulation effect substantially. Since there were no degradation of IBU 274 
occurred, it can be expected that there should be no OPs to be detected.  275 
Table 4 Removal of CIP and IBU by 5 mg/L and 10 mg/L ferrate (VI) 276 
 277 
A number of OPs resulting from the CIP degradation were detected by LC-MS 278 
in ESI positive mode. Besides, most of the OPs for each compound were detected 279 
under both ferrate(VI) dose conditions. Moreover, for most of the detectable products, 280 
their instrumental response in the MS at 10 mg/L ferrate(VI) was stronger than that at 281 
5 mg/L (Table 5), which indicated again the formation of OPs during ferrate(VI) 282 
oxidation. Based on the measured m/z values, the best-fit chemical structures of such 283 
OPs were tentatively proposed by referring to prior knowledge with considerations of 284 
the molecule pattern of target compounds and the mechanism of ferrate(VI) oxidation 285 
(An et al. 2010; De Witte et al. 2008, 2009; Liu et al. 2012; Vasconcelos et al. 2009). 286 
Ferrate(VI) oxidation of organic compounds is via one/two electron transfer, 287 
hydrogen abstraction or oxygen transfer (Huang et al. 2001; Sharma 2010). 288 
Table 5 Response of selected OPs of CIP in the MS 289 
 290 
Seven OPs of CIP are presented in Table 6 with their probable formulas and 291 
chemical structures. Most of the proposed OPs were produced by the transformation 292 
of the piperazinyl moiety of CIP. Besides, the transformation could also happen at the 293 
quinolone rings of CIP which were attacked by ferrate(VI) and this could lead to the 294 
cleavage or hydroxylation of the rings and form OPs, e.g. CIP-1 and CIP-2a. On the 295 
other hand, the attack on the quinolone moiety by ferrate(VI) might lead to the 296 
cleavage of the double bond at the six-member heterocyclic rings and form CIP-2b. 297 
Table 6 OPs formation from the CIP degradation and detected by LC-MS in ESI 298 
positive mode 299 
 300 
Figure 5 gives the probable pathway of CIP degradation during the treatment 301 
by ferrate(VI). The oxidation product, CIP-1, was formed with loss of an ethylene 302 
group from the piperazine group. Further loss of a C2H5N group led to the formation 303 
of CIP-4, while an addition of C=O group on CIP-1 produced CIP-5. Besides, the 304 
ethylamine group in CIP-5 could also be eliminated which yielded CIP-7. Moreover, 305 
the dihydroxylation of the piperazinyl group with the addition of two oxygen atoms 306 
on CIP formed CIP-2a. Further oxidation of one hydroxyl group could lead to the loss 307 
of two hydrogen atoms and then the formation of a keto-derivative of CIP, CIP-3. In 308 
addition, the attack on the quinolone ring of CIP by ferrate(VI) formed CIP-2b. 309 
Finally, CIP-6 was generated by replacing the fluorine atom with a hydroxyl group. 310 
 311 
Fig. 5 Pathways of CIP degradation by ferrate(VI) 312 
 313 
4. Conclusions 314 
The treatment of CIP and IBU in test solution samples by ferrate(VI) was 315 
investigated. Results demonstrated that ferrate(VI) could remove CIP from test 316 
solutions effectively, with at least 70% of removal under the applied experimental 317 
conditions. Besides, ferrate(VI) also had considerable rate constants with CIP at pH 8 318 
and pH 9, with the apparent second-order rate constants of 113.7 ± 6.3 M−1 s−1 and 319 
64.1 ± 1.0 M−1 s−1 at 20?, respectively. Moreover, a number of oxidation products 320 
(OPs) of CIP during ferrate(VI) oxidation were detected and its degradation pathways 321 
were tentatively proposed. In contrast, the removal of IBU by ferrate(VI) was less 322 
than 25%, with its rate constants less than 0.2 M−1 s−1 at pH 8 and pH 9. Besides, no 323 
OPs of IBU was detected during ferrate(VI) oxidation. Generally, raising ferrate(VI) 324 
dose could improve the treatment performance, while the influence of solution pH on 325 
ferrate(VI) performance was not significant at pH 6–9. The attack on the piperazinyl 326 
ring of the CIP by ferrate(VI) appeared to lead to the cleavage or hydroxylation of the 327 
rings, and the attack on the quinolone moiety by ferrate(VI) might lead to the 328 
cleavage of the double bond at the six-member heterocyclic ring. Ferrate(VI) 329 
demonstrated a sound potential to removal CIP and other ERMs-containing 330 
pharmaceuticals in the test solutions. 331 
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Fig. 2 The removal of compounds at 10 μg/L versus solution pH: (a) CIP; and (b) 429 
IBU 430 
 431 
Fig. 3 Degradation of ferrate (VI) versus reaction time in the CIP solution at pH 9 432 
 433 
 434 
Fig. 4 k’ values versus [CIP] at pH 9 435 
 436 
 437 
Fig. 5 Pathways of CIP degradation by ferrate (VI) 438 
 439 
Table 1 Information about CIP and IBU 440 
Compound CAS NO. Chemical structure MW (g·mol-1) pKa Kow 
CIP 85721-33-1 
 
331.35 6.09 0.28 
IBU 15687-27-1 
 
206.29 4.91 3.97 
From SRC PhysProp Database  441 
Table 2 Self-decomposition rates of ferrate (VI) at pH 8 and pH 9 442 
Solvent 
k’self-decomposition, s−1 
pH 8 pH 9 
Water 3.24 × 10−4 3.8 × 10−5 
 443 
Table 3 Apparent second-order rate constants of CIP and IBU at pH 8 and pH 9 444 
Compound 
kapp, (M−1 s−1) 
pH 8 pH 9 
CIP 113.689 ± 6.345 64.131 ± 0.982 
IBU 0.122 ± 0.006 0.0150 ± 0.0002 
 445 
Table 4 Removal of CIP and IBU by 5 mg/L and 10 mg/L ferrate (VI) 446 
Compound 
Ferrate (VI) 
5 mg/L 10 mg/L 
CIP 61% 100% 
IBU 2% 6% 
Table 5 Response of selected OPs of CIP in the MS. 447 
Dosage m/z=262.7 m/z = 305.7 m/z=329.7 m/z = 333.7 m/z=363.7 
5 mg/L 1.7 × 107 5.0 × 105 8.1 × 106 1.9 × 108 7.2 × 106 
10 mg/L 1.4 × 108 7.2 × 106 1.8 × 107 1.0 × 108 2.6 × 107 
 448 
Table 6 OPs formation from the CIP degradation and detected by LC-MS in ESI 449 
positive mode 450 
OP m/z  Molecular Molecular Probable structure 
Weight formula 









CIP-3 361.6 361 C17H16FN3O5 
 
CIP-4 262.7 262 C13H11FN2O3 
 
CIP-5 333.7 333 C16H16FN3O4 
 
CIP-6 329.7 329 C17H19N3O4 
 
CIP-7 290.7 290 C14H11FN2O4 
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